A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Summary

Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at the recommended dose in phase Ia to determine the recommended dose in phase II clinical study (RP2D).

Timeline

Start

2023-08-02

Primary completion

2026-12

Completion

2027-12

Drugs

Indications